Mutant p53 Degrading Compounds for Cancer Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies lack effective methods to restore the functional p53 pathway in cancer cells with mutant p53, which is common in human cancers, hindering the development of targeted treatments.
Innovation Solution
Development of compounds, such as those represented by Formula I, II, and III, which are administered to restore the p53 signaling pathway by targeting and degrading mutant p53 protein and activating p53 family members p73 and p63, thereby promoting tumor suppression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If small molecule compounds are developed to restore p53 pathway in mutant p53 cancer cells, then tumor suppression and apoptosis are improved, but no approved drug exists yet indicating difficulty in achieving functional restoration
Solution Approach 1:
The patent extracts and targets the mutant p53 protein for degradation using small molecule compounds, separating the problematic mutant p53 from the functional p53 pathway. By removing the dominant-negative mutant p53 protein, the pathway can be restored without requiring direct modification of wild-type p53 function.
Solution Approach 2:
The patent employs small molecule compounds as intermediaries that mediate between the mutant p53 protein and the cellular degradation machinery. These compounds bind to mutant p53 and recruit E3 ubiquitin ligases, facilitating selective degradation of the mutant protein while sparing wild-type p53.
2Reliability
If mutant p53 protein is targeted for degradation, then p53 pathway signaling is restored, but direct functional restoration of p53 activity as a DNA-binding transcription factor remains difficult to achieve
Solution Approach 1:
Instead of attempting to directly restore or modify mutant p53 protein structure to regain DNA-binding function, the patent inverts the approach by degrading the mutant protein and allowing endogenous wild-type p53 to restore pathway function naturally. This avoids the complexity of protein structure modification.
Solution Approach 2:
The patent enables the cell's own wild-type p53 protein to self-restore pathway function after mutant p53 degradation. The endogenous wild-type p53 automatically assumes its normal DNA-binding and transcriptional activation roles without requiring external modification or delivery of functional protein.
3Reliability
If p53 family members p73 and p63 are activated to replace mutant p53, then tumor suppressive functions are restored, but mutant p53 must first be removed or inactivated
Solution Approach 1:
The patent performs preliminary degradation of mutant p53 protein before p73 and p63 can effectively exert their tumor suppressive functions. By removing the dominant-negative mutant p53 first, the pathway restoration process is streamlined and more efficient, as p73/p63 activation occurs in a permissive environment without mutant p53 interference.
Data Source
AI summary
The disclosure generally relates to compounds, compositions, and methods for the treatment of cancer by restoring the P53 pathway signaling to repress cancer cell growth.